Physiologically Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition
Open Access
- 16 August 2019
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 8 (10) , 759-768
Abstract
Vincristine is a cytotoxic chemotherapeutic agent used as first-line therapy for pediatric acute lymphocytic leukemia. It is cleared by hepatic oxidative metabolism by CYP3A4 and CYP3A5 and via hepatic (biliary) efflux mediated by P-glycoprotein (P-gp) transporter. Bottom-up physiologically based pharmacokinetic (PBPK) models were developed to predict vincristine disposition in pediatric and adult populations. The models incorporated physicochemical properties, metabolism by CYP3A4/5, efflux by P-gp, and intracellular binding to β-tubulin. The adult and pediatric PBPK models predicted pharmacokinetics (PK) within twofold of the observed PK parameters (area under the curve, terminal half-life, volume of distribution, and clearance). Simulating a higher hypothetical (4.9-fold) pediatric expression of β-tubulin relative to adult improved predictions of vincristine PKs. To our knowledge, this is the first time that intracellular binding has been incorporated into a pediatric PBPK model. Utilizing this PBPK modeling approach, safe and effective doses of vincristine could be predicted.Keywords
This publication has 42 references indexed in Scilit:
- Acute lymphoblastic leukaemiaThe Lancet, 2013
- Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemiaPediatric Blood & Cancer, 2010
- Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled AsthmaNew England Journal of Medicine, 2010
- Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rateEuropean Journal of Cancer, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Tumoral and tissue‐specific expression of the major human β‐tubulin isotypesCytoskeleton, 2010
- A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to ManClinical Cancer Research, 2007
- SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5Drug Metabolism and Disposition, 2006
- Energetics of vinca alkaloid interactions with tubulin isotypes: Implications for drug efficacy and toxicityCell Motility, 1998
- Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemiaThe Journal of Pediatrics, 1994